Cell>Point files investigational new drug application for agent

06/22/2010 | Business Wire

Cell>Point said it has filed with the FDA an investigational new drug application for a Phase Ib/II study of its 99mTc-EC-G imaging agent, which will be used in patients with cardiovascular conditions. The study aims to prove the potential of the agent as an alternative to standard myocardial perfusion imaging agents.

View Full Article in:

Business Wire

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Compliance and Ethics Director
Sysmex America, Inc.
Lincolnshire, IL
Director, Site Quality Management
CareFusion
Palm Springs, CA
Compliance Officer-Medical Products
W. L. Gore
Flagstaff, AZ
Director, Site Quality Management
CareFusion
Minneapolis, MN
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC